EUVIMEDEUVIMED entdecken
Crossref

Revisiting Luteolin Against the Mediators of Human Metastatic Colorectal Carcinoma: A Biomolecular Approach

Ankita Chakraborty, Advaitha Midde, Pritha Chakraborty, Sourin Adhikary, Simran Kumar, Navpreet Arri, Nabarun Chandra Das, Parth Sarthi Sen Gupta, Aditi Banerjee iD, Suprabhat Mukherjee iD

Journal of Cellular Biochemistry · 2025

DOI: 10.1002/jcb.30654 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular Biochemistry, 2025. Verfasst von Ankita Chakraborty und 9 weiteren Autor:innen. Beteiligte Einrichtung: Integrative Biochemistry and Immunology Laboratory, Department of Animal Science, Kazi Nazrul University, Asansol, West Bengal, India. Hauptthemen laut MEDLINE: Luteolin, Colorectal Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 84 Literaturangaben. Gefördert von: Aditi Banerjee received the Richard Schwartz Award from the Department of Pediatrics at the University of Maryland School of Medicine. Suprabhat Mukherjee ackn….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic colorectal carcinoma (mCRC) is one of the prevalent subtypes of human cancers and is caused by the alterations of various lifestyle and diet‐associated factors. β‐catenin, GSK‐3β, PI3K‐α, AKT1, and NF‐κB p50 are known to be the critical regulators of tumorigenesis and immunopathogenesis of mCRC. Unfortunately, current drugs have limited efficacy, side effects and can lead to chemoresistance. Therefore, searching for a nontoxic, efficacious anti‐mCRC agent is crucial and of utmost interest. The present study demonstrates the identification of a productive and nontoxic anti‐mCRC agent through a five‐targets (β‐catenin, GSK‐3β, PI3K‐α, AKT1, and p50)‐based and three‐tier (binding affinity, pharmacokinetics, and pharmacophore) screening strategy involving a series of 30 phytocompounds having a background of anti‐inflammatory/anti‐mCRC efficacy alongside 5‐fluorouracil (FU), a reference drug. Luteolin (a phyto‐flavonoid) was eventually rendered as the most potent and safe phytocompound. This inference was verified through three rounds of validation. Firstly, luteolin was found to be effective against the different mCRC cell lines (HCT‐15, HCT‐116, DLD‐1, and HT‐29) without hampering the viability of non‐tumorigenic ones (RWPE‐1). Secondly, luteolin was found to curtail the clonogenicity of CRC cells, and finally, it also disrupted the formation of colospheroids, a characteristic of metastasis. While studying the mechanistic insights, luteolin was found to inhibit β‐catenin activity (a key regulator of mCRC) through direct physical interactions, promoting its degradation by activating GSK3‐β and ceasing its activation by inactivating AKT1 and PI3K‐α. Luteolin also inhibited p50 activity, which could be useful in mitigating mCRC‐associated proinflammatory milieu. In conclusion, our study provides evidence on the efficacy of luteolin against the critical key regulators of immunopathogenesis of mCRC and recommends further studies in animal models to determine the effectiveness efficacy of this natural compound for treating mCRC in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LuteolinColorectal NeoplasmsHumansbeta CateninNeoplasm MetastasisProto-Oncogene Proteins c-aktGlycogen Synthase Kinase 3 betaCell Line, TumorFluorouracil

Stichwörter der Autor:innen

MD simulationanticancer activityinflammationluteolinmetastatic colorectal carcinomaβ‐catenin

Substanzen

Luteolinbeta CateninProto-Oncogene Proteins c-aktGlycogen Synthase Kinase 3 betaAKT1 protein, humanFluorouracilCTNNB1 protein, human

Autor:innen und Institutionen

  • Integrative Biochemistry and Immunology Laboratory, Department of Animal Science, Kazi Nazrul University, Asansol, West Bengal, India.
  • Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Food Toxicology Laboratory, Food, Drug, and Chemical Toxicology Group, CSIR-Indian Institute of Toxicology Research, Lucknow, Uttar Pradesh, India.
  • School of Biosciences and Bioengineering, D. Y. Patil International University, Pune, Maharashtra, India.

ORCID-Profile: Aditi Banerjee, Suprabhat Mukherjee

Förderung

  • Aditi Banerjee received the Richard Schwartz Award from the Department of Pediatrics at the University of Maryland School of Medicine. Suprabhat Mukherjee ackn…

Zitieren

APA

Chakraborty, A., Midde, A., Chakraborty, P., Adhikary, S., Kumar, S., Arri, N., Chandra Das, N., Sen Gupta, P. S., Banerjee, A., & Mukherjee, S. (2025). Revisiting Luteolin Against the Mediators of Human Metastatic Colorectal Carcinoma: A Biomolecular Approach. Journal of Cellular Biochemistry. https://doi.org/10.1002/jcb.30654

Vancouver

Chakraborty A, Midde A, Chakraborty P, Adhikary S, Kumar S, Arri N, et al. Revisiting Luteolin Against the Mediators of Human Metastatic Colorectal Carcinoma: A Biomolecular Approach. Journal of Cellular Biochemistry. 2025. doi:10.1002/jcb.30654

BibTeX
@article{Chakraborty2025,
  author = {Chakraborty, Ankita and Midde, Advaitha and Chakraborty, Pritha and Adhikary, Sourin and Kumar, Simran and Arri, Navpreet and Chandra Das, Nabarun and Sen Gupta, Parth Sarthi and Banerjee, Aditi and Mukherjee, Suprabhat},
  title = {Revisiting Luteolin Against the Mediators of Human Metastatic Colorectal Carcinoma: A Biomolecular Approach},
  journal = {Journal of Cellular Biochemistry},
  year = {2025},
  doi = {10.1002/jcb.30654}
}
Kostenlos starten →